A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Reduction seen in risk for readmission, wound dehiscence, and hematoma, but no significant differences seen in rates of infection, bleeding ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

GLP-1 drugs currently available for weight loss are administered as once-weekly injections. Verdiva Bio also aims to bring to patients once-a-week dosing, but in a more convenient pill. That would ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

GLP-1 RA drugs help treat diabetes by weight loss, improving blood glucose levels and increasing insulin sensitivity, low ...

The results also showed that the patients taking the GLP-1 RA drugs have a 12 per cent lower risk of hospital re-admission ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

Cardinal Health said on Tuesday it expects annual profit to be at the higher end of its previous forecast range, primarily ...

Patients taking the anti-obesity drugs had about 12% lower risk of hospital re-admission within a month of surgery, compared ...

Taking the ‘GLP-1 receptor agonist’ class of anti-obesity drugs is related with lower rates of post-surgery complications in ...